You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma supports the launch of "Nature Italy"

The Company reaffirms and strengthens its commitment to research and innovation

read more 

CORPORATE

Kedrion announces the appointment of a new CEO

Val Romberg from the USA, one of the most esteemed managers in the industry

read more 

EVENTS

Kedrion supports the 2020 European Hemophilia Consortium Conference

The company renews its commitment alongside the EHC, which continues to support the PARTNERS project

read more 
  1. PLASMA & BIOTHERAPIES - 20-06-2019

    First patient enrolled and treated in Kedrion’s CARES10 clinical study

    Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

    read more 
  2. EVENTS - 20-06-2019

    June 27 and 28 in Trieste (Italy), a two-day event dedicated to hemophilia

    Replacement therapy, personalization and access to treatment are the main themes of the congress organized by Kedrion

    read more 
  3. EVENTS - 29-04-2019

    16th International Hemophilia Congress in Turkey

    A scientific symposium on the prevention and eradication of inhibitors in patients affected by Hemophilia A

    read more 
  4. CORPORATE - 30-01-2019

    Kedrion Biopharma Announces Completion of Enrollment for CARES10

    A Phase 3, Multi-Center Study to Assess a 10% Ig in Adults with Primary Immunodeficiency Disease

    read more 

Pages

For more information please contact: pressoffice@kedrion.com